Enzymatic Therapy Petadolex Review

by Enzymatic Therapy
Enzymatic Therapy Petadolex
5.82 out of 10 based on 0 user ratings
Enzymatic Therapy Petadolex
Enzymatic Therapy Petadolex
Written by: Brain Research Supplements
Date Published: 2012-09-24
5.82 / 10 stars
Enzymatic Therapy Petadolex  Review

Available at...
Amazon.com

Is Enzymatic Therapy Petadolex Right For You?

Enzymatic Therapy Petadolex is marketed as a dietary supplement that promotes Effectiveness in both fast-acting reductions of severity and frequency of migraine attacks as well as their prevention. The company behind this remedy is Enzymatic Therapy. They claim that their product has been available on the European market since 1972 and more than one million people have used it with great results.

The business manufactures various remedies for different conditions and health segments, such as weight management, heart, and energy support. The producers have received numerous prizes for some of their supplements, including Whole Body Cleanse, DGL Ultra and Best of Supplement Awards for Remifemin.

The Petadolex Butterbur extract is claimed to be standardized and patented, resulting in a superior quality formulation, both safe and efficient. This patented extract is claimed to be free of potentially dangerous levels of pyrrolizidine alkaloids (PAs), a class of substances present in certain plants that may lead to liver damage.

$24.13

Ingredients of Enzymatic Therapy Petadolex

Enzymatic Therapy Petadolex includes the following ingredients: Purple Butterbur (Petasites hybridus) as root extract (standardized at 7.5 mg pertains and free of harmful levels of pyrrolizidine alkaloids), medium chain triglycerides, gelatin, vegetable glycerin, water, and riboflavin color.

Rate this post
shareShare on FacebookShare on Google+Pin on Pinterest
Have a comment or question about Enzymatic Therapy Petadolex Review?

(Please Note: Comments or questions which include website links or do not contain positive factual language will not be posted.)

Your email address will not be published.